I have a patient with low follicle‑stimulating hormone (FSH), low anti‑Müllerian hormone (AMH) (0.4 ng/mL), low luteinizing hormone (LH), and amenorrhea. How should I counsel her?

Counseling a Patient with Low FSH, Low LH, Low AMH (0.4 ng/mL), and Amenorrhea

Your patient most likely has functional hypothalamic amenorrhea (FHA), and the low AMH of 0.4 ng/mL does NOT necessarily reflect true ovarian reserve depletion—it may be artificially suppressed by the low gonadotropin state and can potentially recover with treatment. 1

Understanding the Hormone Pattern

The combination of low FSH, low LH, and amenorrhea points toward hypothalamic-pituitary dysfunction rather than ovarian failure. According to the 2017 Endocrine Society guidelines, patients with FHA characteristically show:

• Low or low-normal LH and FSH (often with FSH higher than LH)
• Low estradiol (<50 pg/mL, often <20 pg/mL)
• Preserved GnRH response (distinguishing it from organic hypogonadotropic hypogonadism) 1

Critical distinction: If FSH and LH were elevated with low estradiol, this would indicate primary ovarian insufficiency (POI). Your patient's low gonadotropins suggest the problem originates in the brain, not the ovaries.

The AMH Paradox in Hypogonadotropic States

The low AMH (0.4 ng/mL) is likely misleading in this context. Recent evidence demonstrates that:

• In women with hypogonadotropic hypogonadism, AMH levels are falsely low because gonadotropin suppression reduces follicular development 1, 2
• AMH can increase significantly with gonadotropin stimulation—in one study, AMH rose from 0.20 to 1.26 ng/mL during treatment 3
• AMH reflects the growing follicular pool responsive to gonadotropins, not the underlying primordial follicle reserve 3
• In FHA without polycystic ovarian morphology, AMH correlates with androgen levels and reflects hypothalamic suppression rather than true ovarian reserve 4, 5

Bottom line for counseling: Tell your patient that her low AMH likely reflects the suppressed hormonal state, not irreversible ovarian damage. With restoration of normal hypothalamic-pituitary function, AMH levels typically recover 4, 5.

Complete the Diagnostic Workup

Before finalizing the diagnosis, obtain these additional tests per Endocrine Society guidelines 1:

Essential labs:

• Pregnancy test (β-hCG) first
• Estradiol (expect <50 pg/mL in FHA)
• TSH and free T4 (rule out thyroid dysfunction)
• Prolactin (rule out hyperprolactinemia)
• Total testosterone and DHEA-S if any signs of hyperandrogenism

Additional screening if indicated:

• Complete blood count, comprehensive metabolic panel
• Consider inflammatory markers (ESR, CRP) if chronic illness suspected
• Hemoglobin A1C if glucose abnormalities present

Imaging:

• Pelvic ultrasound to assess ovarian morphology and antral follicle count—this provides additional information about ovarian reserve independent of the suppressed hormonal state 1

Identify the Underlying Cause

FHA results from chronic activation of the hypothalamic-pituitary-adrenal axis. Systematically assess for:

Energy deficit:

• Excessive exercise relative to caloric intake
• Restrictive eating or eating disorders
• Low body weight or recent weight loss
• Calculate BMI

Psychological stressors:

• Perfectionism, high need for approval
• Major life stressors
• Anxiety or mood disorders

Medical conditions:

• Chronic inflammatory diseases
• Type 1 diabetes (high risk for disordered eating)
• Celiac disease or malabsorption

Long-Term Health Consequences to Discuss

The amenorrhea itself poses serious health risks beyond fertility concerns:

Bone health (most critical):

• Prolonged hypoestrogenism causes irreversible bone loss
• Increased fracture risk that persists even after recovery
• Peak bone mass acquisition is compromised in young women

Cardiovascular risks:

• Adverse lipid profiles
• Endothelial dysfunction
• Increased visceral fat accumulation
• Potential for accelerated atherosclerosis 1

Other concerns:

• Cognitive effects (unclear but under investigation)
• Mood and anxiety symptoms

Emphasize urgency: These complications develop silently and require proactive management, not just addressing fertility when desired.

Treatment Strategy

First-line approach (non-pharmacologic):

Address the underlying cause directly:

• Increase caloric intake if energy deficit present
• Reduce exercise intensity/volume
• Weight restoration if underweight (target BMI >18.5 kg/m²)
• Cognitive-behavioral therapy for stress management
• Treatment of eating disorders if present

This approach can restore menstruation in many patients and is the only intervention that addresses root causes.

Bone protection:

• Calcium 1200-1500 mg daily
• Vitamin D to maintain 25-OH vitamin D >30 ng/mL
• Weight-bearing exercise (balanced, not excessive)

Hormonal therapy considerations:

• Physiologic estrogen replacement may be considered for bone health, but does not address the underlying problem
• Combined oral contraceptives are commonly used but provide less bone benefit than physiologic estrogen
• Transdermal estrogen with cyclic progesterone more closely mimics normal physiology

Fertility Counseling

Reassure your patient that fertility is often preserved despite the low AMH:

If pregnancy desired now:

After complete fertility workup, treatment options include 1:

1. Pulsatile GnRH (first-line but unavailable in US)—96% cumulative pregnancy rate after 6 cycles
2. Gonadotropin therapy (FSH + LH activity)—requires careful monitoring, higher multiple pregnancy risk
3. Clomiphene citrate—only if sufficient endogenous estrogen present (generally not effective in FHA)

If pregnancy desired later:

• Restoration of normal menstrual cycles through lifestyle modification is the goal
• AMH levels may increase as hypothalamic-pituitary function recovers 4, 5
• Ovarian reserve assessment should be repeated after cycle restoration

Key Counseling Points

Frame the conversation around these messages:

1. The diagnosis is likely reversible with appropriate lifestyle and psychological interventions
2. Low AMH does not mean ovarian failure in this context—it reflects suppressed gonadotropin stimulation
3. Bone health is the immediate concern, not just future fertility
4. Treatment must address root causes (energy balance, stress, weight) rather than just replacing hormones
5. Fertility outcomes are generally good with appropriate ovulation induction when pregnancy is desired
6. Time is important—prolonged amenorrhea causes cumulative damage, particularly to bone

Common Pitfalls to Avoid

• Don't misinterpret low AMH as POI without considering the gonadotropin context—elevated FSH/LH would indicate POI, not low values 1
• Don't rely solely on hormonal contraception without addressing underlying causes—this masks the problem without treating it
• Don't delay bone density assessment if amenorrhea has been prolonged (>6-12 months)
• Don't assume infertility based on the low AMH—ovarian response to gonadotropins is often preserved 2, 3